Following negative Phase 3 trial results, Sanofi announced that it will not be pursuing approval of its experimental therapy tolebrutinib for primary progressive multiple sclerosis (PPMS). Meanwhile, a decision from the U.S. Food and Drug Administration (FDA) on tolebrutinib’s use in nonrelapsing secondary progressive MS (SPMS) is likely to be delayed again, the company said. Sanofi had […]
The post Sanofi’s experimental MS therapy tolebrutinib suffers twin setbacks appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com